Teva Eyes ‘80% Of Off-Patent Opportunities’ For Generics And Biosimilars
As Israeli Firm Identifies New Long-Term Financial Targets For 2027
Teva’s president and CEO Kåre Schultz provided fresh long-term financial targets for the company in the wake of the firm agreeing in principle to settle opioid-related claims in the US – but will the architect of Teva’s restructuring remain beyond his current November 2023 contract?
